Back to search results

HARP: Heart Attack Research Program - Platelet Sub-Study

This observational study, called HARP, is looking into how platelets (tiny blood cells that help stop bleeding) work in women who have had a heart attack (myocardial infarction, or MI). Researchers want to understand the genetic makeup of platelets and their role in heart attacks. You may be able to join if you are a woman between 21 and 99 years old and have recently experienced symptoms of a heart attack, such as chest pain, along with objective evidence like elevated troponin levels or specific changes on an electrocardiogram (ECG). The study aims to examine markers related to platelet activity and cardiovascular disease risk over one year to understand the cellular and molecular reasons for heart attacks in women. This study is currently unclear about its recruitment status.

Study design
This is an observational study involving women who have had a heart attack, with a planned enrollment of 350 participants.
What's involved
Blood will be collected during initial catheterization and again two months after your heart attack for platelet testing.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for one year to examine platelet activity and cardiovascular disease risk markers.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03022552

Heart Attack Research Program: Platelet Sub-Study (HARP)

Recruiting
Not specifiedAges 21–99Observational
NYU Langone Health
~350 participants
Updated 2026-04-20 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Examination of Platelet Activity Markers
Measured over 1 year
+2 more outcomes measured

Conditions

Myocardial Infarction

Explore related trials

Myocardial InfarctionStable Angina

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • Harmony R Reynolds, MD · PRINCIPAL_INVESTIGATOR · NYU Langone Medical Center

Who to contact

Jeffrey Berger, MD
[email protected]
212 263 4004
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Acute ischemic symptoms compatible with diagnosis of MI, such as chest pain or anginal equivalent symptoms at rest or new onset exertional anginal equivalent symptoms
Objective evidence of MI (either or both of the following):
Elevation of troponin to above the laboratory upper limit of normal (ULN)
ST segment elevation of ≥1mm on 2 contiguous ECG leads
Willing to provide informed consent and comply with all aspects of the protocol
Administration of aspirin at least 1 hour before cardiac catheterization
Administration of thienopyridine (e.g., clopidogrel, ticagrelor) at least 1 hour before cardiac catheterization
Women and men with ≥50% of any major epicardial vessel on invasive angiography may participate

Exclusion

Recent use of vasospastic agents, such as cocaine, triptans, or ergot alkaloids (≤1 month)
Alternate explanation for troponin elevation, such as hypertensive urgency, acute exacerbation of heart failure, chronic elevation due to kidney disease, pulmonary embolism, cardiac trauma
Pregnancy
Thrombolytic therapy for STEMI (qualifying event)
Use of any of the following medications:
Platelet antagonists (except aspirin and thienopyridines) within 7 days
NSAIDs (e.g., ibuprofen, naproxen) within 3 days.
Thrombocytopenia (platelet count \<100,000)
Thrombocytosis (platelet count \>500,000)
Anemia (hemoglobin \<9 mg/dl)
Hemorrhagic diathesis

What this trial measures

  • Examination of Platelet Activity Markers1 year
  • Examination of Markers of Cardiovascular Disease Risk1 year

    This will include additional examination of known thrombosis, Inflammation, metabolic disease, and lipids/lipoprotein markers.

  • Cellular and molecular mechanism of myocardial infarction in women1 year

    To further investigate this mechanism, recent advances in microRNA, RNA, DNA expression profiling, and plasma and serum collections will be used.